Skip to main content
. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661

Figure 1.

Figure 1

D-VTd, daratumumab, bortezomib, thalidomide, dexamethasone; D-VRd, daratumumab, bortezomib, lenelidomide, dexamethasone; wKRd_D, weekly carfilzomib, lenalidomide, dexamethasone, daratumumab; IxaRd-D, ixazomib, lenalidomide, dexamethasone, daratumumab; D-VCd and CyBorD-D, daratumumab, cyclophosphamide, bortezomib, dexamethasone. *≥ CR not available; ^MRD status not available.